Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses

L J Brandes1, R J Arron, R P Bogdanovic

  • 1Department of Medicine, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.

Cancer Research
|July 1, 1992
PubMed

Insights

Tricyclic antidepressants and fluoxetine may stimulate tumor growth. Studies show these antidepressants accelerated tumor development in rodents, suggesting potential risks in cancer patients.

Area of Science:

  • Pharmacology
  • Oncology
  • Cell Biology

Background:

  • Tricyclic antidepressants (e.g., amitriptyline) and fluoxetine interact with intracellular histamine receptors.
  • These receptors are linked to anti-estrogen binding sites, and a related compound stimulates tumor growth in vivo.
  • The structural similarity suggests a potential for antidepressants to influence tumor development.

Purpose of the Study:

  • To investigate whether amitriptyline and fluoxetine stimulate tumor growth and/or development in rodent models.
  • To assess these effects at concentrations relevant to human therapeutic doses for depression.

Main Methods:

  • Rodent models were used, including syngeneic tumor transplants (fibrosarcoma, melanoma) and a mammary carcinogenesis model (DMBA-induced).
  • Animals received daily injections of saline, amitriptyline, or fluoxetine.
  • Tumor latency, weight, metastasis, and DNA synthesis were measured; experiments were blinded.

Main Results:

  • Amitriptyline and fluoxetine significantly increased the incidence and accelerated the development of fibrosarcoma and mammary tumors.
  • Tumor latency decreased by 30-40%, and tumor frequency more than doubled in antidepressant-treated groups.
  • Antidepressants stimulated DNA synthesis in fibrosarcoma cells in vitro, correlating with accelerated tumor growth in vivo.

Conclusions:

  • Amitriptyline and fluoxetine demonstrate tumor-growth-stimulating properties in rodent models.
  • These findings suggest a potential risk of antidepressants influencing tumor progression.
  • Further research is warranted to understand the clinical implications for cancer patients undergoing antidepressant treatment.